CompletedNCT01192906
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
Medication studyAges 18+Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Carson and 112 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateDecember 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 624
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, Brazil, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT01192906
- Official title
Show the full official title
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Recruitment & locations
CompletedCarson, United States · Oceanside, United States · San Diego, United States
89 more locations
- Hartford, United States
- Norwalk, United States
- North Miami, United States
- Atlanta, United States
- Chicago, United States
- Hoffman Estates, United States
- Joliet, United States
- Lake Charles, United States
- Shreveport, United States
- St Louis, United States
- Omahac, United States
- Cedarhurst, United States
- Jamaica, United States
- Rochester, United States
- Allentown, United States
- Norristown, United States
- Philadelphia, United States
- Salvador, Brazil
- Goiânia, Brazil
- Belo Horizonte, Brazil
- Curitiba, Brazil
- Rio de Janeiro, Brazil
- Pelotas, Brazil
- Porto Alegre, Brazil
- São Paulo, Brazil
- Calgary, Canada
- Medicine Hat, Canada
- Vancouver, Canada
- Victoria, Canada
- Halifax, Canada
- Burlington, Canada
- Hamilton, Canada
- Mississauga, Canada
- Montreal, Canada
- Verdun, Canada
- San Miguel, Chile
- Santiago, Chile
- Valdivia, Chile
- Berlin, Germany
- Bochum, Germany
- Cologne, Germany
- Freiburg im Breisgau, Germany
- Hamburg, Germany
- München, Germany
- Nuremberg, Germany
- Daugovpils, Latvia
- Jelgava, Latvia
- Liepāja, Latvia
- Kaunas, Lithuania
- Šilutė, Lithuania
- Vilnius, Lithuania
- Assen, Netherlands
- Groningen, Netherlands
- Choroszcz, Poland
- Kielce, Poland
- Lublin, Poland
- Piekary Śląskie, Poland
- Skorzewo, Poland
- Tuszyn, Poland
- Warsaw, Poland
- Bojnice, Slovakia
- Bratislava, Slovakia
- Rimavská Sobota, Slovakia
- Svidník, Slovakia
- Barcelona, Spain
- Madrid, Spain
- Oviedo, Spain
- Salamanca, Spain
- Zamora, Spain
- Hualian Town, Taiwan
- Kaohsiung City, Taiwan
- Taichung, Taiwan
- Tainan, Taiwan
- Tainan County, Taiwan
- Taipei, Taiwan
- Ankara, Türkiye
- Diyarbakır, Türkiye
- Gaziantep, Türkiye
- Istanbul, Türkiye
- Manisa, Türkiye
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Glevakha Kyviv Region, Ukraine
- Kharkiv, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Vinnytsia, Ukraine
- Türkiye
Questions about this study
Who is behind this study?
The study sponsor is Hoffmann-La Roche.
Did this study involve medication?
Yes. The study involved medication, including Placebo and bitopertin [RO4917838].
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia